Fundación Con Vida

Ten-year overall survival in patients with breast cancer and pathogenic/probably pathogenic germ line variants who attend genetic consultation at an oncology center in the city of Medellín

Germline pathogenic or likely pathogenic variants (P/LPVs) are present in approximately 10% of breast cancer cases. However, the clinical outcomes and genetic distribution in Latin American populations remain understudied. This study aimed to estimate 10-year overall survival (OS...

Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study

Trastuzumab biosimilar EG12014 (Herwenda ® ; EirGenix/Sandoz) was approved by the European Medicines Agency (EMA) in 2023. We aim to demonstrate equivalent efficacy, and to compare safety, immunogenicity, and pharmacokinetic (PK) profiles, of EG12014 and reference trastuzumab (re...